Dec 5, 2014
Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem
Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem
Somerset, N.J. (PRWEB) December 04, 2014
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement with Swiss-based development-stage biopharmaceutical company SELLAS Life Sciences Group (SELLAS), to…
View On WordPress
